解码TP53-突变性急性髓性白血病的分子驱动因素:临床影响和预后见解
Lin-Ya Wang1, Hai-Tao Gao1, Qiang Fu1
1Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.
British journal of haematology
|December 1, 2025
概括
分子特征显著影响TP53-突变性急性髓性白血病 (AML) 的预后. 特定的TP53突变部位和RUNX1-RUNX1T1等同时发生的突变会影响患者的治疗结果和治疗反应.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- TP53突变与急性髓性白血病 (AML) 的预后不佳有关.
- 了解TP53-突变AML的独特临床和分子特征对于改善患者的治疗结果至关重要.
研究的目的:
- 研究TP53-突变AML的临床特征和分子格局.
- 在这个患者队列中确定影响生存和治疗反应的预后因素.
主要方法:
- 对193名TP53突变AML患者的回顾性分析.
- 治疗方案的比较,包括venetoclax加上低甲基化剂 (VEN+HMA) 与"3+7"疗法.
- 评估特定TP53突变部位,共同突变及其与临床结果的相关性,如总体存活率 (OS) 和复合完全缓解率 (CRc).
主要成果:
- 与"3+7"方案 (30.2%) 相比,接受VEN+HMA治疗的患者显示显著改善CRc率 (53.8%).
- TP53 V272突变与较低的复发率 (0%) 有关.
- 单个TP53突变突击,CEBPA bZIP框架内突变和RUNX1-RUNX1T1融合基因与优越的OS相关.
- 多变量分析确定了RUNX1-RUNX1T1融合,RUNX1突变和FLT3-ITD突变作为OS的显著预后因素.
结论:
- 分子因素,特别是TP53突变部位和共突变,在确定TP53突变AML的预后方面发挥着关键作用.
- 在TP53-突变AML中,VEN+HMA疗法表现出卓越的疗效.
- 识别特定的分子变化可以指导TP53-突变AML患者的风险分层和治疗策略.
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


